ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/017/SRR24639217/SRR24639217_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/015/SRR24639215/SRR24639215_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/013/SRR24639213/SRR24639213_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/011/SRR24639211/SRR24639211_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/017/SRR24639217/SRR24639217_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/014/SRR24639214/SRR24639214_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/012/SRR24639212/SRR24639212_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/018/SRR24639218/SRR24639218_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/015/SRR24639215/SRR24639215_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/018/SRR24639218/SRR24639218_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/016/SRR24639216/SRR24639216_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/010/SRR24639210/SRR24639210_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/012/SRR24639212/SRR24639212_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/016/SRR24639216/SRR24639216_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/011/SRR24639211/SRR24639211_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/010/SRR24639210/SRR24639210_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/013/SRR24639213/SRR24639213_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR246/014/SRR24639214/SRR24639214_2.fastq.gzprimaryOK200GenomicsCancer Hospital Chinese Academy of Medical Scienceshttps://www.ebi.ac.uk/ena/browser/view/PRJNA973945Homo sapiensThese findings delineate the mechanism of OTUB2 epigenetic silencing in ovarian cancer, demonstrate the critical roles of OTUB2/SNX29P2 in inhibiting glycolysis and eliciting cuproptosis in cancer cells and suggest that CA9 inhibitor treatment is a promising therapeutic option for OTUB2-silenced tumors. To investigate the downstream pathway regulated by OTUB2/SNX29P2, we performed RNA sequencing (RNA-seq) in ES-2 cells expressing EV, OTUB2 or SNX29P2. Overall design: RNA-seq of ES-2 cells expressing EV, OTUB2 or SNX29P2ENAfalseOTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibitionOTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition2025-09-242024-04-23PRJNA973945GSE2327729606